Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ether. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL5207262 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TSHRLMNAHSD17B10THRB | |
| Ether SCHEMBL9353265 | 0.93 | ALDH1A1 (0.52) | ALDH1A1TSHRLMNAHSD17B10THRB | |
| Ether SCHEMBL164114 | 0.93 | — | — | |
| Ether SCHEMBL1234081 | 0.93 | ALDH1A1 (0.52) | ALDH1A1TSHRLMNAHSD17B10THRB | |
| Ether SCHEMBL3336965 | 0.93 | ALDH1A1 (0.52) | ALDH1A1TSHRLMNAHSD17B10THRB | |
| Ether SCHEMBL7531159 | 0.93 | ALDH1A1 (0.52) | ALDH1A1TSHRLMNAHSD17B10THRB | |
| Ether SCHEMBL28112568 | 0.91 | ALDH1A1 (0.46) | ALDH1A1TSHRLMNAHSD17B10THRB | |
| Ether SCHEMBL1417335 | 0.90 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNAHSD17B10THRB | |
| Ether SCHEMBL1492008 | 0.90 | ALDH1A1 (0.46) | ALDH1A1TSHRLMNAHSD17B10THRB | |
| Ether SCHEMBL907948 | 0.90 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNAHSD17B10THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112062696-B | Production method of N-acetyltaurine magnesium | 瑟纳法姆工业合成有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-11053194-B2 | Production process for magnesium N-acetyl taurinate | SYNAPHARM INDUSTRIAL SYNTHESIS (BE) | 2021-07-06 | — | — | US | disclosed |
| US-20200392078-A1 | Production process for magnesium N-acetyl taurinate | SYNAPHARM INDUSTRIAL SYNTHESIS (BE) | 2020-12-17 | — | — | US | disclosed |
| EP-1902717-A2 | Vasopressin antagonist and oxytocin antagonist | Otsuka Pharmaceutical Company, Limited (JP) | 2008-03-26 | — | — | EP | disclosed |
| EP-0620003-B1 | VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST | OTSUKA PHARMA CO LTD (JP) | 2008-01-16 | — | — | EP | disclosed |
| US-6943267-B1 | compounds structurally resemble the substrates of the enzymes, but have nonhydrolyzable mono protonated thiophosphonate salts; chromatography or distillations not required | UTAH STATE UNIVERSITY (US) | 2005-09-13 | — | — | US | disclosed |
| US-20050049431-A1 | Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases | UTAH STATE UNIVERSITY | 2005-03-03 | — | — | US | disclosed |
| US-6140330-A | USEFUL AS PROTEIN KINASE INHIBITOR; FOR TREATMENT OF AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, MULTIPLE SCLEROSIS, PSORIASIS, ETC., VARIOUS ALLERGIC DISEASES SUCH AS CROHN'S DISEASE, ASTHMA | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-10-31 | — | — | US | disclosed |
| EP-0858452-A1 | THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-08-19 | — | — | EP | disclosed |
| WO-1998004536-A1 | THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1998-02-05 | — | — | WO | disclosed |
| US-4443475-A | ANTIARRHYTHMIA AGENTS, ANTIDEPRESSANTS | CAVAZZA CLAUDIO (IT) | 1984-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049431-A1 | Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases | PPME1, MTMR1, PTPRE | ALDH1A1 1993/4885TSHR 1052/4885LMNA 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.